According to the Complaint, Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose “mission” is to “redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.” Navacaprant, Neumora’s flagship therapeutic candidate, is a once-daily oral kappa opioid receptor antagonist aimed at treating major depressive disorder (“MDD”).

This lawsuit was filed against Neumora, nine Individual Defendants, and six Underwriter Defendants.

Neumora's initial public offering commenced on September 15, 2023.

The Complaint alleges that the Offering Documents issued in connection with Neumora's IPO contained false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn’s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. When the true details entered the market, the lawsuit claims that investors suffered damages.

Plaintiff re-filed the Complaint on February 7, 2025.